|
![]() |
|||
|
||||
OverviewTranslating Regenerative Medicine to the Clinic reviews the current methodological tools and experimental approaches used by leading translational researchers, discussing the uses of regenerative medicine for different disease treatment areas, including cardiovascular disease, muscle regeneration, and regeneration of the bone and skin. Pedagogically, the book concentrates on the latest knowledge, laboratory techniques, and experimental approaches used by translational research leaders in this field. It promotes cross-disciplinary communication between the sub-specialties of medicine, but remains unified in theme by emphasizing recent innovations, critical barriers to progress, the new tools that are being used to overcome them, and specific areas of research that require additional study to advance the field as a whole. Volumes in the series include Translating Gene Therapy to the Clinic, Translating Regenerative Medicine to the Clinic, Translating MicroRNAs to the Clinic, Translating Biomarkers to the Clinic, and Translating Epigenetics to the Clinic. Full Product DetailsAuthor: Jeffrey Laurence (Weill Cornell Medical College, New York, NY, USA) , Pedro Baptista (Group Leader and Visiting Professor, Health Research Institute of Aragon, Zaragoza, Spain, and Carlos III University, Madrid, Spain) , Anthony Atala (Professor, Wake Forest Institute for Regenerative Medicine, USA)Publisher: Elsevier Science Publishing Co Inc Imprint: Academic Press Inc Dimensions: Width: 21.60cm , Height: 2.30cm , Length: 27.60cm Weight: 1.180kg ISBN: 9780128005484ISBN 10: 0128005483 Pages: 354 Publication Date: 08 December 2015 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Manufactured on demand ![]() We will order this item for you from a manufactured on demand supplier. Table of ContentsIntroduction: Regenerative Medicine for Cardiovascular Disease-A Good Start PART I: STEM CELLS: Chapter 1: Introduction and Overview of Stem Cells Chapter 2: Mechanistic Insights from Pathologic Perspective Chapter 3: Large Animal Models to Study Stem Cell Therapy Section I. Body’s Native Repair Mechanisms Chapter 4. Evolution of understanding of the mechanisms of repair Chapter 5: Impact of Age on Stem Cell Function Section II: Autologous Bone Marrow Chapter 6: Bone Marrow Mononuclear Cells Chapter 7: Chronic Limb Ischemia Chapter 8: Chronic/Refractory Angina Chapter 9: Acute Myocardial Infarction A. European Experience: Andreas Zeiher B. US Experience: Jay Traverse Chapter 10: Chronic Ischemic Heart Failure Section III: Autologous Adipose Derived Regenerative Cells Chapter 11: Adipose Tissue Section IV: Allogeneic Alternatives to Autologous Bone Marrow Chapter 12: Overview of MSCs Chapter 13: Allogeneic vs Autologous Source: Comparative Effects Chapter 14: Use of MSCs for AMI Chapter 15: Combined Cell Strategies Chapter 16: Heart Failure Section V: Cardiac Progenitor Cells Chapter 17: C-Kit+ cells Chapter 18: Cardiospheres Section VI: Other Allogeneic Sources of Stem Cells Chapter 19: Umbilical Cord, Placenta, Endometrium Section VII. Genetic Engineering/Cell Transformation Chapter 20: Genetic Engineering of Fibroblasts to Cardiomyocytes Chapter 21: Transformation to inducible Pleuripotent Stem Cells Chapter 22: Transformation to MAPC's Section VIII: METHODS OF DELIVERY: Chapter 23. Transcoronary and Endocardial Chapter 24. Retrograde and Epicardial Part II. TISSUE ENGINEERING: Chapter 25. Epicardial Patch Chapter 26. Matrix Scaffolds Chapter 27. Matrix plus cells Chapter 28. Biomaterial Chapter 29: Organogenesis Part III. GENE THERAPY: Chapter 30: Pre-clinical Identification of target genes Chapter 31: SERCA-2a gene for recovery of inotropic function Chapter 32: SDF-1 Gene for Heart Failure Non-Inotropic Mechanisms Chapter 33: Gene Therapy for Angiogenesis: Chronic Limb Ischemia Chapter 34: Stem Cells Target Gene Transfected Stem Cells Part IV: FUTURE DIRECTIONS: Chapter 35: CCTRN: Past, Present, and Vision for the Future Chapter 36: Signature of Responders-lessons from Bio-Repository Chapter 37: Adjunctive therapy with LVADs for Recovery Chapter 38: Trials in Non-Ischemic Heart Failure Chapter 39: Enhancing Stem Cell Homing for Tissue Repair Chapter 40: Stroke: Pre-Clinical and Clinical Trial Data SUMMARYReviewsAuthor InformationDr Laurence is pursuing the pathophysiology of cardiovascular and skeletal abnormalities linked to HIV disease and its therapies at Weill Cornell. Dr Laurence is the editor-in-chief of Translational Medicine, which Elsevier co-publishes with the CSCTR. Dr. Pedro Baptista is originally from Portugal, where he graduated from the School of Pharmacy of the University of Lisbon. He completed his doctoral dissertation at the Gulbenkian Ph.D. Program in Biomedicine. He is currently a Group Leader at the Health Research Institute of Aragon in Zaragoza, Spain and the founder of the Organ Bioengineering and Regenerative Medicine Laboratory at this institution. He is also an Assistant Professor at the Department of Biomedical and Aerospace Engineering at University Carlos III of Madrid, Spain. He is one of the founders and the Deputy Chairman of the European Association for the Study of the Liver Consortium for Regenerative Hepatology and currently the Deputy Secretary General and an elected Board Governor of the European Society for Artificial Organs. His current research focuses on creating bioengineered livers that can finally make the long-term transplantation of these lab-grown organs a reality.Dr. Pedro Baptista is originally from Portugal, where he graduated from the School of Pharmacy of the University of Lisbon. He completed his doctoral dissertation at the Gulbenkian Ph.D. Program in Biomedicine. He is currently a Group Leader at the Health Research Institute of Aragon in Zaragoza, Spain and the founder of the Organ Bioengineering and Regenerative Medicine Laboratory at this institution. He is also an Assistant Professor at the Department of Biomedical and Aerospace Engineering at University Carlos III of Madrid, Spain. He is one of the founders and the Deputy Chairman of the European Association for the Study of the Liver Consortium for Regenerative Hepatology and currently the Deputy Secretary General and an elected Board Governor of the European Society for Artificial Organs. His current research focuses on creating bioengineered livers that can finally make the long-term transplantation of these lab-grown organs a reality. Anthony Atala, MD, is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology. Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. Fifteen applications of technologies developed in Dr. Atala's laboratory have been used clinically. He is Editor of 25 books and 3 journals. Dr. Atala has published over 800 journal articles and has received over 250 national and international patents. Dr. Atala was elected to the Institute of Medicine of the National Academies of Sciences, to the National Academy of Inventors as a Charter Fellow, and to the American Institute for Medical and Biological Engineering. Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the National Institutes of Health Bioengineering Consortium, and the National Cancer Institute’s Advisory Board. He is a founding member of the Tissue Engineering Society, Regenerative Medicine Foundation, Regenerative Medicine Manufacturing Innovation Consortium, Regenerative Medicine Development Organization, and Regenerative Medicine Manufacturing Society. Tab Content 6Author Website:Countries AvailableAll regions |